🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

91 results for “Bristol-Myers Squibb / Pfizer EEIG” Clear

  1. deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib

    Bristol-Myers Squibb / Pfizer EEIG

    Juvenile Psoriatic Arthritis (JPsA)

    phase 3 small molecule active

    1 trial

  2. A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  3. BBP-398, CETUXIMAB, ADAGRASIB

    Bristol-Myers Squibb / Pfizer EEIG

    Oncology, NSCLC and CRC

    phase 2 small molecule active

    1 trial

  4. BET-Inhibitor, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, FEDRATINIB

    Bristol-Myers Squibb / Pfizer EEIG

    DIPSS-Intermediate or High Risk Myelofibrosis

    phase 2 small molecule active

    1 trial

  5. BMS-986470, BMS-986470, N/A, BMS-986470

    Bristol-Myers Squibb / Pfizer EEIG

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  6. BMS-986517

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  7. BMS-986523, BMS-986523

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  8. BMS-986525, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. BNT327 50 mg ml, BNT327 20 mg ml, IPILIMUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, Ipilimumab

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  10. CISPLATIN, Ipilimumab, PACLITAXEL, Nivolumab Subcutaneous, CARBOPLATIN, PEMETREXED

    Bristol-Myers Squibb / Pfizer EEIG

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  11. CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., PACLITAXEL, anti-NKG2A mAb, CARBOPLATIN, PEMETREXED DISODIUM

    Bristol-Myers Squibb / Pfizer EEIG

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, PACLITAXEL, TOPOTECAN, farletuzumab ecteribulin

    Bristol-Myers Squibb / Pfizer EEIG

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial

  13. DASATINIB, Dasatinib, dasatinib, dasatinib

    Bristol-Myers Squibb / Pfizer EEIG

    Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib

    phase 2 small molecule active

    1 trial

  14. DEXAMETHASONE, DEXAMETHASONE, LENALIDOMIDE, Empliciti 400 mg powder for concentrate for solution for infusion., LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE

    Bristol-Myers Squibb / Pfizer EEIG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  15. FDC Nivolumab + Relatlimab + rHuPH20 Injection, Nivolumab/Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab Subcutaneous

    Bristol-Myers Squibb / Pfizer EEIG

    Melanoma

    phase 2 small molecule active

    1 trial

  16. Florquinitau F-18, Sodium Chloride, PRX005

    Bristol-Myers Squibb / Pfizer EEIG

    Early Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  17. MRTX1719

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab

    Bristol-Myers Squibb / Pfizer EEIG

    Neoplasms by site

    phase 2 small molecule active

    1 trial

  19. Nivolumab Subcutaneous, BMS986482, FDC Nivolumab + Relatlimab + rHuPH20 Injection, BMS986482, BEVACIZUMAB

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  20. OPDIVO 10 mg/mL concentrate for solution for infusion., Anti-Fucosyl GM1 PET Tracer, ETOPOSIDE, CARBOPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Ipilimumab

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovarian Cancer (OC)

    phase 2 small molecule active

    1 trial

  22. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., DARZALEX 20 mg/mL concentrate for solution for infusion, Relatlimab, Relatlimab

    Bristol-Myers Squibb / Pfizer EEIG

    MSI Negative Colorectal Cancer, MSI Positive Colorectal Cancer

    phase 2 small molecule active

    1 trial

  23. OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous, 0.9% Sodium Chloride Injection, Avastin 25 mg/ml concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced/metastatic hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  24. OPDIVO 10 mg/mL concentrate for solution for infusion., Stivarga 40 mg film-coated tablets, anti-CTLA-4 NF Probody® mAb

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources